Factors affecting bladder dose in gynecologic intracavitary brachytherapy

Basit Öğe Kaydı
dc.authoridKose, Mehmet Faruk/0000-0001-6136-5597
dc.authoridKURTMAN, CENGIZ/0000-0001-9865-2370
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidAdli, Mustafa/ABH-5809-2020
dc.authorwosidKurtman, Cengiz/AAA-2389-2021
dc.authorwosidKose, Mehmet Faruk/ABE-9977-2021
dc.contributor.authorAdli, Mustafa
dc.contributor.authorGaripagaoglu, Melahat
dc.contributor.authorKocak, Zafer
dc.contributor.authorKoese, M. Faruk
dc.contributor.authorKurtman, Cengiz
dc.date.accessioned2024-06-12T11:02:52Z
dc.date.available2024-06-12T11:02:52Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe purpose of this study is to investigate factors affecting bladder ICRU reference point dose in gynecologic cancer patients receiving intracavitary brachytherapy. Forty seven different intracavitary HDR brachytherapy applications were performed using tandem-ovoid (n=25), vaginal ovoid (n= 17) and tandem-cylinder (n=5) in 43 patients diagnosed with cervical (n=29), endometrial (n=12) and vaginal (n=2) carcinoma. Effect of applicator type, number of pregnancy and delivery, and type of hysterectomy in operated patients on ICRU bladder reference point dose was investigated. ICRU bladder reference point dose was significantly higher in tandem-cylinder applications than in vaginal ovoid alone or tandem-ovoid applications (p=0.009). No difference was found between vaginal ovoid alone and tandem-ovoid applications. Number of pregnancy and delivery had no effect on bladder dose. Bladder reference point dose was significantly higher in patients underwent type 3 hysterectomy compared to type 1-2 hysterectomy (p<0.00 1). Several factors affect bladder dose during gynecologic intracavitary brachytherapy. Patient and applicator related factors should be evaluated together and any necessary changes needed should be made in the treatment plan accordingly.en_US
dc.identifier.endpage8en_US
dc.identifier.issn1306-133X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-41949119271en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21451
dc.identifier.volume18en_US
dc.identifier.wosWOS:000258429700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGynecologic Intracavitary Brachytherapyen_US
dc.subjectBladder Doseen_US
dc.subjectICRUen_US
dc.subjectSurgeryen_US
dc.subjectUterine Cervixen_US
dc.subjectRadiation-Therapyen_US
dc.subjectCarcinomaen_US
dc.subjectCanceren_US
dc.subjectComplicationsen_US
dc.subjectHysterectomyen_US
dc.subjectRadiotherapyen_US
dc.subjectIrradiationen_US
dc.titleFactors affecting bladder dose in gynecologic intracavitary brachytherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu